Published in final edited form as:

Med Hypotheses. 2019 January ; 122: 92–97. doi:10.1016/j.mehy.2018.10.024.

The cause-effect relationship between bone loss and Alzheimer's disease using statistical modeling

Natalia Loskutova, MD, PhD¹, Amber S. Watts, PhD², and Jeffrey M. Burns, MD³

¹American Academy of Family Physicians National Research Network

²University of Kansas, Lawrence, Kansas, USA

³University of Kansas School of Medicine, Kansas City, KS, USA

Abstract

Background: Animal studies provide strong evidence that the CNS directly regulates bone remodeling through the actions of the hypothalamus via two distinct pathways, the neural (mediated by leptin) arm and neurohumoral (mediated by neurohormones and growth factors) arm. The impact of AD on central regulatory mechanisms of bone mass is not known.

Objectives: To test a model that assesses the relationship between hypothalamic atrophy and bone loss in Alzheimer's disease (AD) and potential mediation through neural (leptin) and neurohumoral (insulin-like growth factor -1, IGF-1) mechanisms.

Hypotheses: AD-related hypothalamic structural change alters neural and neurohumoral regulatory systems of bone remodeling and contributes to bone loss in early AD.

Design: A secondary data analysis of data obtained in a two-year longitudinal study with path analysis and longitudinal mediation modeling.

Participants: The data were collected as a part of the University of Kansas Brain Aging Project, a two-year observational study of 71 older adults with early stage AD and 69 non-demented controls.

Measurements: Demographic characteristics and measures of bone density, body composition, and hypothalamic volume, serum levels of leptin, growth hormone, and IGF-1 were collected.

Results: Hypothalamic atrophy and bone loss were observed in AD group and were associated. Data modeling suggests that bone loss may precede measurable changes in the brain. Leptin increased over two years in AD and the increase in leptin was associated with hypothalamic

---

Correspondence to: Natalia Y. Loskutova, American Academy of Family Physicians National Research Network, 11400 Tomahawk Creek Pkwy, Leawood, KS 66211, 800-274-2237, nloskutova@hotmail.com.

Author Contributions: All authors meet the criteria for authorship stated in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals and agree with the presented findings. This work has not been published before nor is being considered for publication in another journal.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest: The authors and co-authors have no relevant financial or personal conflict of interests.

atrophy. However, changes in leptin or IGF-1 levels did not mediate the relationship between hypothalamic atrophy and bone loss.

Conclusions: This study extends previous findings by suggesting that bone loss in AD may be related to neurodegenerative changes (atrophy) in the hypothalamus. Further studies are needed to explore the role of brain atrophy and mediating mechanisms in bone loss. Further exploring temporal relationship between bone loss and AD may have an important diagnostic value.

Keywords

bone loss; Alzheimer's disease; hypothalamus; CNS; leptin; statistical modeling

INTRODUCTION

Alzheimer's disease (AD) and bone loss are among the most common conditions associated with aging. Low bone mineral density (BMD) and increased rates of bone loss are associated with cognitive decline and a higher risk of developing AD.(1–3) Individuals with all stages of AD have lower bone density and an increased incidence of fractures.(4–6) Some evidence suggests that bone loss may occur years before the onset of cognitive AD manifestations.(2, 3, 7) Although AD and bone loss share many common risk factors and exacerbating mechanisms,(8) whether alterations in these factors are a cause or a consequence of AD remains unclear(9).

Animal studies provide strong evidence that the central nervous system (CNS) directly regulates bone remodeling through the hypothalamus via two distinct pathways, the neural and neurohumoral arms.(10–12) Briefly, the neural arm involves hypothalamic control of bone remodeling through increased sympathetic nervous system output mediated by leptin. The neurohumoral arm involves hypothalamic control of the anterior pituitary hormones, such as growth hormone (GH) and insulin-like growth factor-1 (IGF-1) (13) The evidence of AD-related dysfunction in both the neurohumoral and neural arms is abundant.(14–17) The association between leptin levels and BMD in humans however, range from negative(18–20) or no association(21, 22) to positive relationships.(23, 24)

We previously demonstrated that low bone density in early-stage AD was associated with lower volumes of the hypothalamus.(25) We then proposed a hypothesis that AD-related hypothalamic structural change alters neural and neurohumoral regulatory systems of bone remodeling and contributes to bone loss in early AD. The purpose of the present study was to test the hypothesis stated above and further extend previous observations by assessing the roles of leptin and GH-IGF-1 in mediating relationship between hypothalamic structural changes and bone loss in AD. We used statistical modeling to explore hypothetical cause-effect relationships between bone loss and hypothalamic regulation in a two-year longitudinal study of individuals with early AD and older controls without AD.

MATERIALS AND METHODS

Study participants and demographics

Data for this study were collected through the University of Kansas Brain Aging Project, a case-control, 2-year longitudinal study assessing the role of lifestyle factors in brain aging. The presence and severity of AD were determined by the Clinical Dementia Rating (CDR) and CDR sum of boxes score.(26) Seventy-one patients with early-stage AD (CDR 0.5, n=57 and CDR 1.0, n=14) and 69 non-demented elderly control participants (CDR 0) were enrolled in the Brain Aging Project. We excluded individuals with unstable diagnosis from baseline to follow up (N=4 reverters, N = 9 converters) and unknown dementia status at baseline. Baseline clinical and demographic characteristics of these individuals, exclusion criteria, and detailed clinical, bone density, body composition, neuroimaging, and blood sample assessment methodology have been reported previously(27) and can be found in Supplementary Text S1.

Statistical analysis

Statistical analyses were conducted using SPSS (PASW statistics 22, SPSS Inc., Chicago, IL) and Mplus.(28) Continuous variables were summarized as means $\pm$ standard deviation (SD), and categorical variables were summarized by ratio. Independent samples t-tests and Mann-Whitney U test were used for analyzing group differences in continuous variables, and chi-square statistics were used for categorical data. Paired t-test, repeated measures ANOVA or Wilcoxon Signed Rank exact test for two-related samples (longitudinal), two-tailed, were used to test change in variables over two years as deemed appropriate. Pearson and Spearman correlations were used to investigate the univariate relationships between variables. Analyses were conducted separately for individuals with and without AD.

Path analyses and hypothetical causal modeling

The development of the models of effects of neurodegeneration on central control of bone remodeling via neural and neurohumoral hypothalamic regulatory arms was informed by animal studies confirming such biological regulatory mechanisms,(11) evidence of hypothalamic structural damage and dysfunction in AD, and our prior observations of an association between hypothalamic volume and bone density. The first hypothetical model we tested used change scores (difference between baseline and follow-up scores) and tested direct effects of hypothalamic atrophy on bone loss and indirect effects mediated by changes leptin and GH-IGF-1. Indirect effects were calculated via bootstrapping estimation. The causal *a priori* theoretical assumptions (what causes what) are shown in the path diagrams by arrows (Figure 1).

Because several different models can be fit equally well to the same covariance matrix (29) and the selection of the direction of hypothetical causation can be arbitrary, we also tested an alternative hypothesis, that changes in BMD precede changes in hypothalamic volume. We used an improved application of the “half-longitudinal” mediation model, adjusting for baseline values when estimating follow up outcomes, to explore the direction of causal association.(30) We tested the autocorrelations for each variable with itself between baseline and follow up and the cross lags between variables from baseline to follow up. Correlations

between the variables at baseline and follow up were estimated. Given the longitudinal mediation, we included baseline values for a more accurate estimate of change processes assuming autoregressive effects.(31) The significance level for change over time and correlation analyses was set as two-tailed $p = 0.05$; all variables related to the proposed hypothesis that correlated with bone loss at $p < 0.10$ were included in exploratory predictive modeling and path analysis; and the root mean square error of approximation (RMSEA) was set at < 0.05 .

RESULTS

Sample characteristics and changes over time

BMD and bone loss: The baseline and follow-up characteristics for participants in the study are presented in Table 1. There was no difference in age and gender distribution between the groups at baseline and follow up. BMD declined from baseline in both groups ($p < 0.05$) with greater bone loss in AD compared to the non-demented controls in total body (2.10% in AD vs. 0.95% in non-demented, $p = 0.03$).

Changes in body composition: Groups were similar at baseline in BMI, percent body fat, and waist-to-hip circumference ratio. Over two years however, the AD group had a slight increase in the percent body fat (34.9 ± 11.1 vs. 34.0 ± 10.4 at baseline, $p < 0.05$) and waist-to-hip circumference ratio (0.91 ± 0.07 vs. 0.87 ± 0.08 at baseline, $p < 0.001$) while no change was found in non-demented controls.

Hormone levels: There was no difference between the groups at baseline in measures of serum leptin, total IGF-1, and GH. Levels of IGF-1 declined slightly over two years in both AD and non-demented with no difference between groups. Leptin levels in the control group remained unchanged over two years (13.1 ± 10.3 ng/ml at baseline vs. 13.3 ± 10.0 ng/ml at follow-up, $p = 0.84$). In the AD group leptin levels increased significantly (14.9 ± 11.5 ng/ml vs. 21.9 ± 19.8 ng/ml at follow-up, $p < 0.001$).

Decline in physical activity in both groups: The average baseline level of physical activity of the control group was comparable to that reported for community dwelling elderly persons in the US (PASE score = 130.7 ± 55.5). (32) Baseline habitual physical activity level was lower in AD (102.8 ± 76.5 $p = 0.02$) than in non-demented. Both groups declined over two years and with a greater decline in physical activity in AD vs. non-demented ($p = 0.07$).

Whole brain and hypothalamic atrophy: As expected, whole brain atrophy rate was higher in AD (2.2% vs. 1.2% in non-demented per year, $p < 0.001$). Hypothalamic volumes were smaller in AD group at baseline (0.65 ± 0.10 cm³ vs. 0.72 ± 0.12 cm³ in non-demented, $p = 0.001$), consistent with previously reported results,(33) and at follow-up (0.54 ± 0.08 cm³ in AD vs. 0.58 ± 0.08 cm³ in non-demented, $p = 0.006$).

Predictors of bone loss

We correlated changes in total body BMD with baseline measures of vitamin D, demographic characteristics, baseline levels of physical activity, two-year change in physical activity, adiposity, whole brain atrophy, and hypothalamic atrophy. As expected, in the non-demented group, decline in the total body BMD was related to decline in physical activity ($\beta = 0.23$, $p = 0.09$), age ($\beta = -0.31$, $p = 0.02$) and female gender ($\beta = -0.32$, $p = 0.02$), together explaining 28% of total variance in bone loss. In the AD group, decline in the total body BMD was associated with lower baseline vitamin D level ($\beta = -0.41$, $p = 0.02$) and hypothalamic atrophy ($\beta = 0.30$, $p = 0.06$), which together explained 23.1% of total variance in bone loss (Table 2).

Next, all variables related to the proposed hypothesis that correlated with bone loss ($p < 0.10$) were included in further analysis. No relationship was observed between baseline GH levels and bone density or bone loss or mediating variables (leptin and IGF-1); therefore, GH was not included in further analyses. Due to significant correlation between leptin and body fat, we corrected the levels of leptin for total fat mass and used the level of leptin in pkg/ml per gram of fat. (34, 35)

Path analysis

Hypothetical model #1—Based on the correlation matrix and the theoretical reasoning that the hypothalamic volume change over two years caused bone loss via changes in the central hypothalamic mediators and unknown mechanisms not tested in the study, we arbitrarily set the model #1 as follows: hypothalamic atrophy (hypothalamic volume) on BMD via the separate pathways of IGF-1 and Leptin. In this model, we simultaneously tested the direct effects of hypothalamic volume on BMD and indirect effects of hypothalamic atrophy on BMD via the separate pathways of IGF-1 and leptin.

For the AD group (Figure 1a), we found significant direct effects of hypothalamic atrophy on bone loss. Leptin was not a significant predictor of BMD but it was independently related with IGF-1 and hypothalamic atrophy. No significant indirect effects were found. Hypothalamic volume loss significantly predicted increased leptin levels, though it was unrelated to IGF-1. The correlation between Leptin and IGF-1 was significant ($r = 0.43$, $p < 0.05$).

For the normal-control group, (Figure 1b), we found significant direct effects of Leptin on BMD, but none of the other variables was a significant predictor. No significant indirect effects were found. Hypothalamic atrophy did not significantly predict changes in IGF-1, Leptin or BMD.

Hypothetical model #2—Since in the AD group Leptin did not have a direct effect on BMD but it was independently related with IGF-1 and hypothalamic atrophy, we tested an alternative biologically plausible model that examined the potential role of changes in leptin and IGF-1 on bone loss (Figure 2). As Leptin was a non-significant predictor of bone loss in the demented group, we adjusted the model by removing the direct path from Leptin to BMD, but allowed for an indirect effect of Leptin via either hypothalamic atrophy or

IGF-1. Hypothalamic atrophy continued to have direct effects on BMD and predicted Leptin ($-.23, .02$). The indirect effect of hypothalamic atrophy on BMD via a complete Leptin – IGF-1 path did not reach significance ($0.2, p=0.16$). Leptin was positively and significantly associated with IGF-1 ($0.41, <.001$). Furthermore, the indirect effect of Leptin – IGF-1 path on BMD reached statistical significance ($-.08, .05$). The model demonstrated good fit for the data in the AD group ($X^2(df)=7(6)$; CFI = 1.0; RMSEA <0.001). This model did not fit the data and was not relevant in the normal control group.

Longitudinal mediation analysis

We next explored other potential causal directions of relationships between change in hypothalamic volume, leptin, IGF-1, and bone density across two time points two years apart using longitudinal mediation analysis separately for the AD and normal-control groups. We specifically did not restrict the direction of the effects among variable in this analysis.

Contradictory to initial hypothetical effect direction, we found a strong direct effect of baseline BMD on follow up hypothalamic volume ($\beta = .50, p <.001$) in AD and a modest effect in non-demented ($\beta = .27, p <.05$); i.e., low baseline BMD predicted lower hypothalamic volume at follow-up. Baseline hypothalamic volume, leptin, and IGF did not predict follow-up hypothalamic volume. Though BMD predicted increased leptin levels ($\beta = -.21, p =.01$) in AD, this did not mediate the relationship between BMD and hypothalamic volume. Baseline BMD was not related to follow-up IGF-1 in either group. Fit indices suggest this model fit the data well ($X^2(df)=7/7$, CFI = 1.00; RMSEA = .00).

DISCUSSION

In our previous work, we demonstrated a relationship between low BMD and low hypothalamic volumes in the earliest clinical stages of AD.(5) Here, we reported that bone loss and hypothalamic atrophy are observed in AD in a longitudinal study. We further tested a hypothesis that neurodegenerative changes in AD may influence bone mass via alteration in central regulatory mechanisms of bone remodeling. In this exploratory longitudinal study with a smaller number of participants, we observed: 1) moderate association between hypothalamic atrophy and bone loss in the expected direction that, however failed to achieve the threshold value for $p \leq 0.05$, possibly due to a small sample size and 2) more atrophy in the hypothalamus was associated with increase in leptin over two years in the AD group. However, we failed to find any evidence of a complete indirect mediation between hypothalamic structural changes and bone loss through leptin or IGF-1 in either group.

Genetic and pharmacological manipulations in animal models suggest the importance of central regulation of bone homeostasis through hypothalamic control via both neural pathways and hypothalamo-pituitary hormonal mechanisms.(11, 36, 37) Consistent with previous evidence documenting leptin as bone catabolic factor, we observed the relationship between higher baseline leptin and lower baseline and follow-up bone density in the non-demented group. Leptin levels were not related to bone density or bone loss in the AD group. Based on our results we speculate that the patterns of the relationship among IGF-1, leptin, and bone density may differ in AD and non-demented aging.

This study suggests that bone loss in AD may be related to neurodegenerative changes (atrophy) in the hypothalamus with different mechanisms involved in bone loss in aging and AD. These changes may be related to a cascade of events including increase in peripheral levels of leptin. In our study, the peripheral leptin levels increased significantly in AD participants but not in non-demented controls over two years. This observation is in contrast with several other studies reporting an association between AD and lower levels of leptin. (38–40) Why increase in level of leptin over two years in early AD was observed in our study remains unclear. Some studies suggest that this may be related to abnormal functioning of hypothalamus-regulated timekeeping and clock genes (e.g., nocturnin) that are found to be involved in shifting differentiation of mesenchymal stem cells towards adipogenesis in aging.(41–44) Additionally, reports on association between leptin levels and cognitive function or AD are highly contradictory and this association needs to be further explored.(45, 46) Nevertheless, the model of independent neural and neurohumoral arms that contribute to bone loss in individuals with AD is perhaps oversimplified. The relationship between leptin and bone are far more complex than initially proposed in earlier animal experiments.(47, 48) The co-dependent relationships among brain, bone, fat, and metabolism should be further investigated in normal and pathological conditions in humans and animal models to gain a better understanding of these interrelationships and to provide a basis for future clinical applications.

The causal assumption for hypothesis testing in this study was based on the theoretical reasoning and data from animal models. Since, however, AD participants were already diagnosed with mild AD and had lower BMD at the beginning of the study(5) the true epidemiological association between bone loss and AD remains an open question. The mediation analysis in our study demonstrated that low baseline BMD was predictive of lower hypothalamic volume at follow up in AD and to the lesser extent in non-demented. Several epidemiologic studies support the same observation, reporting that low bone density and accelerated bone loss are associated with higher risk for developing AD or cognitive decline later on.(3, 7, 49) It seems unlikely that low bone density causes AD. Our observations rather suggest that bone loss may precede clinical signs of dementia or brain structural changes in AD.

The initial hypothesis tested in this study implied an effect-cause type of association, where AD causes bone loss. Our path analysis modeling of change over two years suggests that an effect-cause type of association where AD causes bone loss is plausible although needs to be further tested and confirmed by other studies. Though structural changes in the hypothalamus were associated with bone loss, it is possible that functional changes in brain regulatory mechanism in preclinical stages of AD may have played initial causal role in decline in BMD. Alternatively, the effect-effect scenario cannot be ruled out. In this case, both bone loss and AD are the effects of some common underlying cause. Recent studies in AD suggest that evident physical decline such as loss of body mass, sarcopenia, and functional decline precede cognitive and anatomical neuroimaging brain changes in AD. This evidence suggests the presence of systemic changes in clinically unrecognized stages of disease or a long-standing trait that predisposes one to developing bone loss and AD.

The results of our study should be interpreted with caution due to exploratory nature of the study and several marginally significant observations. Statistically modeled hypothetical causation may not be necessarily correct in a biological model and is most likely an oversimplification. The measures were taken at two time points two years apart, limiting the ability to draw causal inference from the analyses. Additionally, our conclusions were based on peripheral levels of leptin and IGF-1. Furthermore, a consideration should be given when interpreting our study results as we adjusted the levels of leptin by fat in calculating changes over time for inclusion in mediation and path analysis models. Our measures were taken once in the morning and did not assess differences in fluctuations of these hormones. Much variance in bone loss remained unexplained by potential involvement of central regulatory mechanisms within our model. Additional or alternative mechanisms such as change in sex hormones, actual activity of the sympathetic nervous system, detailed nutritional status, and effects of other local and systemic mediators may contribute to these relationships in the very early stages. A relatively small sample size may have resulted in several marginally significant observations and did not allow us to explore the effects of gender on observed relationships or test more complex mediations, including gender dimorphism in the circulating leptin levels; i.e., women have higher circulating leptin levels and lower bone density than men. Additionally, the study was conducted over two years, and longer periods may be needed in order to assess dementia progression and clinically significant bone loss.

Altogether, we are the first to explore the relationship between hypothalamic volume and bone loss in early AD. We conclude that it is conceivable that central regulatory leptin-dependent mechanisms of bone mass may be disturbed by neurodegeneration as evident by different patterns of the relationships between leptin and bone density in AD. However, detailed mechanisms of bone loss in AD and causal and temporal relationships between AD and bone loss need to be further investigated. Additionally, the relationship between low baseline BMD and lower hypothalamic volume at follow up suggests that bone loss may precede noticeable structural changes in the hypothalamus.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding: This study was supported by grants R03AG026374 and R21AG029615 from the National Institute of Aging, K23NS058252 from the National Institute on Neurological Disorders and Stroke and by generous support from the University of Kansas Endowment Association.

Sponsor's Role: The sponsor was not involved in the study design, data analysis and interpretation or reporting of this work.

REFERENCES

1. Yaffe K, Browner W, Cauley J, Launer L, Harris T. Association between bone mineral density and cognitive decline in older women. *Journal of the American Geriatrics Society* 1999 10;47(10):1176–82. [PubMed: 10522949]
2. Tan ZS, Seshadri S, Beiser A, Zhang Y, Felson D, Hannan MT, et al. Bone mineral density and the risk of Alzheimer disease. *Archives of neurology* 2005 1;62(1):107–11. [PubMed: 15642856]

3. Zhou R, Deng J, Zhang M, Zhou HD, Wang YJ. Association between Bone Mineral Density and the Risk of Alzheimer's Disease. *Journal of Alzheimer's disease : JAD* 2010 12 27.
4. Melton LJ, 3rd, Beard CM, Kokmen E, Atkinson EJ, O'Fallon WM. Fracture risk in patients with Alzheimer's disease. *Journal of the American Geriatrics Society* 1994 6;42(6):614–9. [PubMed: 8201146]
5. Loskutova N, Honea RA, Vidoni ED, Brooks WM, Burns JM. Bone Density and Brain Atrophy in Early Alzheimer's Disease. *Journal of Alzheimer's disease : JAD* 2009 8 3.
6. Wang HK, Hung CM, Lin SH, Tai YC, Lu K, Liliang PC, et al. Increased risk of hip fractures in patients with dementia: a nationwide population-based study. *BMC neurology* 2014 9 12;14:175. [PubMed: 25213690]
7. Chang KH, Chung CJ, Lin CL, Sung FC, Wu TN, Kao CH. Increased risk of dementia in patients with osteoporosis: a population-based retrospective cohort analysis. *Age* 2014 4;36(2):967–75. [PubMed: 24347180]
8. Friedman SM, Menzies IB, Bukata SV, Mendelson DA, Kates SL. Dementia and Hip Fractures. *Geriatric Orthopaedic Surgery & Rehabilitation* 2010 11 1, 2010;1(2):52–62. [PubMed: 23569663]
9. Downey CL, Young A, Burton EF, Graham SM, Macfarlane RJ, Tsapakis EM, et al. Dementia and osteoporosis in a geriatric population: Is there a common link? *World journal of orthopedics* 2017 5 18;8(5):412–23. [PubMed: 28567345]
10. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. *Nature* 2003 5 15;423(6937):349–55. [PubMed: 12748654]
11. Takeda S Central control of bone remodeling. *Biochemical and biophysical research communications* 2005 3 18;328(3):697–9. [PubMed: 15694403]
12. Sharan K, Yadav VK. Hypothalamic control of bone metabolism. *Best practice & research Clinical endocrinology & metabolism* 2014 10;28(5):713–23. [PubMed: 25256766]
13. Murray RD, Adams JE, Shalet SM. A densitometric and morphometric analysis of the skeleton in adults with varying degrees of growth hormone deficiency. *The Journal of clinical endocrinology and metabolism* 2006 2;91(2):432–8. [PubMed: 16278268]
14. Ishii M, Iadecola C. Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology. *Cell metabolism* 2015 9 9.
15. Raskind MA, Peskind ER, Halter JB, Jimerson DC. Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease. *Archives of general psychiatry* 1984 4;41(4):343–6. [PubMed: 6703854]
16. Raskind MA, Peskind ER, Holmes C, Goldstein DS. Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. *Biological psychiatry* 1999 9 15;46(6):756–65. [PubMed: 10494443]
17. Elrod R, Peskind ER, DiGiacomo L, Brodtkin KI, Veith RC, Raskind MA. Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. *The American journal of psychiatry* 1997 1;154(1):25–30. [PubMed: 8988954]
18. Cock TA, Auwerx J. Leptin: cutting the fat off the bone. *Lancet* 2003 11 8;362(9395):1572–4. [PubMed: 14615115]
19. Maimoun L, Coste O, Puech AM, Peruchon E, Jaussent A, Paris F, et al. No negative impact of reduced leptin secretion on bone metabolism in male decathletes. *Eur J Appl Physiol* 2008 2;102(3):343–51. [PubMed: 17943305]
20. Oh KW, Lee WY, Rhee EJ, Baek KH, Yoon KH, Kang MI, et al. The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. *Clin Endocrinol (Oxf)* 2005 8;63(2):131–8. [PubMed: 16060905]
21. Peng XD, Xie H, Zhao Q, Wu XP, Sun ZQ, Liao EY. Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. *Clin Chim Acta* 2008 1;387(1–2):31–5. [PubMed: 17884030]
22. Di Carlo C, Tommaselli GA, Di Spiezio Sardo A, Sammartino A, Attianese W, Gargano V, et al. Longitudinal evaluation of serum leptin and bone mineral density in early postmenopausal women. *Menopause* 2007 May-Jun;14(3 Pt 1):450–4. [PubMed: 17242633]

23. Oguz S, Tapisiz OL, Aytan H, Gunyeli I, Erdem S, Tuncay G, et al. Is leptin a significant predictor of bone mineral density in postmenopausal Turkish women? *Rheumatol Int* 2009 2;29(4):393–6. [PubMed: 18818925]
24. Zoico E, Zamboni M, Di Francesco V, Mazzali G, Fantin F, De Pergola G, et al. Relation between adiponectin and bone mineral density in elderly post-menopausal women: role of body composition, leptin, insulin resistance, and dehydroepiandrosterone sulfate. *J Endocrinol Invest* 2008 4;31(4):297–302. [PubMed: 18475046]
25. Loskutova N, Honea RA, Brooks WM, Burns JM. Reduced limbic and hypothalamic volumes correlate with bone density in early Alzheimer's disease. *Journal of Alzheimer's disease : JAD* 2010;20(1):313–22. [PubMed: 20164583]
26. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology* 1993 11;43(11):2412–4.
27. Burns JM, Cronk BB, Anderson HS, Donnelly JE, Thomas GP, Harsha A, et al. Cardiorespiratory fitness and brain atrophy in early Alzheimer disease. *Neurology* 2008 7 15;71(3):210–6. [PubMed: 18625967]
28. Muthen B, Asparouhov T, Rebollo I. Advances in behavioral genetics modeling using Mplus: applications of factor mixture modeling to twin data. *Twin Res Hum Genet* 2006 6;9(3):313–24. [PubMed: 16790142]
29. Mathieu JE, Taylor SR. Clarifying conditions and decision points for mediational type inferences in Organizational Behavior. *Journal of Organizational Behavior* 2006;27(8):1031–56.
30. Cole DA, Maxwell SE. Testing mediational models with longitudinal data: questions and tips in the use of structural equation modeling. *J Abnorm Psychol* 2003 11;112(4):558–77. [PubMed: 14674869]
31. Little TD, Wang LL, Watts AS, Anderson RA, Little TD. *Common Fallacies in Quantitative Research Methodology* 'Oxford University Press'.
32. Washburn RA, McAuley E, Katula J, Mihalko SL, Boileau RA. The physical activity scale for the elderly (PASE): evidence for validity. *Journal of clinical epidemiology* 1999;52(7):643–51. [PubMed: 10391658]
33. Loskutova N, Honea RA, Brooks WM, Burns JM. Reduced limbic and hypothalamic volumes correlate with bone density in early Alzheimer's disease. *Journal of Alzheimer's disease : JAD* 20(1):313–22.
34. Broekhuizen R, Vernooij JH, Schols AM, Dentener MA, Wouters EF. Leptin as local inflammatory marker in COPD. *Respiratory medicine* 2005 1;99(1):70–4. [PubMed: 15672852]
35. Paiva ES, Andretta A, Batista ED, Lobo M, Miranda RC, Nisihara R, et al. Serum levels of leptin and adiponectin and clinical parameters in women with fibromyalgia and overweight/obesity. *Archives of endocrinology and metabolism* 2017 May-Jun;61(3):249–56. [PubMed: 28226002]
36. Martin A, David V, Malaval L, Lafage-Proust MH, Vico L, Thomas T. Opposite effects of leptin on bone metabolism: a dose-dependent balance related to energy intake and insulin-like growth factor-I pathway. *Endocrinology* 2007 7;148(7):3419–25. [PubMed: 17431002]
37. Milewicz T, Krzysiek J, Janczak-Saif A, Sztelfko K, Krzyczkowska-Sendrakowska M. Age, insulin, SHBG and sex steroids exert secondary influence on plasma leptin level in women. *Endokrynol Pol* 2005 Nov-Dec;56(6):883–90. [PubMed: 16821206]
38. Johnston JM, Hu WT, Fardo DW, Greco SJ, Perry G, Montine TJ, et al. Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. *Current Alzheimer research* 2014 2;11(2):165–74. [PubMed: 24359504]
39. Khemka VK, Bagchi D, Bandyopadhyay K, Bir A, Chattopadhyay M, Biswas A, et al. Altered serum levels of adipokines and insulin in probable Alzheimer's disease. *Journal of Alzheimer's disease : JAD* 2014;41(2):525–33. [PubMed: 24625795]
40. Baranowska-Bik A, Bik W, Styczynska M, Chodakowska-Zebrowska M, Barcikowska M, Wolinska-Witort E, et al. Plasma leptin levels and free leptin index in women with Alzheimer's disease. *Neuropeptides* 2015 8;52:73–8. [PubMed: 26070219]
41. Kawai M, Green CB, Horowitz M, Ackert-Bicknell C, Lecka-Czernik B, Rosen CJ. Nocturnin: a circadian target of Pparg-induced adipogenesis. *Ann N Y Acad Sci* 3;1192:131–8.

42. Kawai M, Green CB, Lecka-Czernik B, Douris N, Gilbert MR, Kojima S, et al. A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-gamma nuclear translocation. *Proceedings of the National Academy of Sciences of the United States of America* 6 8;107(23):10508–13.
43. Kirkland JL, Tchkonja T, Pirtskhalava T, Han J, Karagiannides I. Adipogenesis and aging: does aging make fat go MAD? *Exp Gerontol* 2002 6;37(6):757–67. [PubMed: 12175476]
44. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. *Aging Cell* 2004 12;3(6):379–89. [PubMed: 15569355]
45. Oania R, McEvoy LK. Plasma leptin levels are not predictive of dementia in patients with mild cognitive impairment. *Age and ageing* 2015 1;44(1):53–8. [PubMed: 25349150]
46. Romo ML, Schooling CM. Examining the Causal Role of Leptin in Alzheimer Disease: A Mendelian Randomization Study. *Neuroendocrinology* 2017;105(2):182–8. [PubMed: 28419997]
47. Gimble JM. Leptin's balancing act between bone and fat. *J Bone Miner Res* 2011 8;26(8):1694–7. [PubMed: 21698664]
48. Lee EB. Obesity, leptin, and Alzheimer's disease. *Ann N Y Acad Sci* 2011 12;1243:15–29. [PubMed: 22211890]
49. Lui LY, Stone K, Cauley JA, Hillier T, Yaffe K. Bone loss predicts subsequent cognitive decline in older women: the study of osteoporotic fractures. *Journal of the American Geriatrics Society* 2003 1;51(1):38–43. [PubMed: 12534843]

Figure 1.

Hypothetical model #1 of the relationship between hypothalamic volume change and bone loss in the AD group (1a) and non-demented controls (1b); BMD – bone mineral density; IGF-1-insulin-like growth factor 1; the arrows indicate the direction of hypothetical causation; β coefficients displayed along the arrows. Hypothalamic atrophy - Hypothalamic volume.

Figure 2.

Alternative hypothetical model #2 of the relationship between hypothalamic volume change and bone loss in the AD group; BMD – bone mineral density; IGF-1-insulin-like growth factor 1; the arrows indicate the direction of hypothetical causation; β coefficients displayed along the arrows. * $p < .05$, ** $p < .01$, *** $p < .001$

Table 1.

Sample characteristics at baseline and change over two years

	Baseline		Change over time (, baseline minus follow-up)		p-value	
	Non-demented (n=64)	Early AD (n=58)	Non-demented (n=63)	Early AD (n=58)	baseline	
Age, y	73.8 ± 6.8	75.4 ± 6.3			ns	
Gender, F/M	34/30	33/25			ns	
Vitamin D, ng/ml	27.5 ± 8.0	24.1 ± 8.7	-	-	*	-
MMSE	29.4 ± 0.8	26.2 ± 3.1	0.3 ± 1.1	3.6 ± 5.4	***	***
Growth Hormone, ng/ml	0.90 ± 0.94	0.85 ± 1.14	-	-	ns	-
Insulin-like Growth Factor -1, ng/ml	118.9 ± 49.7	116.9 ± 44.3	35.7 ± 33.5	30.3 ± 30.9	ns	ns
Leptin, ng/ml	12.6 ± 10.0	14.8 ± 11.4	-0.2 ± 6.0	-7.3 ± 11.8	ns	*
BMI, kg/m ²	26.2 ± 3.8	25.8 ± 3.8	0.4 ± 1.3	-0.8 ± 1.8	ns	ns
Body Fat, %	33.6 ± 8.8	34.0 ± 10.4	0.04 ± 2.3	-1.1 ± 4.3	ns	*
Waist/hip Circumference	0.87 ± 0.10	0.87 ± 0.08	-0.2 ± 0.08	-0.3 ± 0.06	ns	*
Total Bone Density, g/cm ²	1.16 ± 0.11	1.12 ± 0.12	0.01 ± 0.03	0.02 ± 0.03	t	*
%	-	-	-0.95 ± 2.7%	-2.1 ± 3.1%	-	*

Data represent means ± SD unless otherwise stated; AD – Alzheimer's disease; MMSE – Mini Mental State Exam; BMI – body mass index

*
P 0.05**
P 0.001***
P 0.0001

ns – not significant.

Table 2.

Univariate correlates of bone density at baseline and percent change in bone density from baseline

	BMI	Lean Mass	Fat Mass	25OHD	Leptin	HGH	IGF-1	HV
ND BMD	0.26 *	0.70 ***	0.15	0.18	-0.25 **	-0.21	0.31 *	0.01
AD BMD	0.32 *	0.64 ***	0.08	0.12	-0.07	-0.05	0.13	0.25 **
	BMI	Lean Mass	Fat Mass	Baseline 25OHD	Leptin	Baseline HGH	IGF-1	HV
ND BMD	-0.09	-0.12	-0.11	-0.10	-0.23	-0.18	0.007	-0.01
AD BMD	-0.004	-0.08	-0.02	0.33 *	-0.08	-0.2	0.22	-0.29 **

ND non-demented; BMD – total body bone mineral density; AD – Alzheimer's disease; BMI – body mass index (kg/m^2); Fat and lean masses in kg; 25OHD-serum levels of vitamin D; HGH – human growth hormone; IGF-1 – total serum insulin-like growth factor 1; HV – hypothalamic volume in cm^3

* P 0.05

** P<0.01

*** P 0.0001

- for all but BMD = absolute change over two years.